Relationship Between Coronary Microvascular Dysfunction and Improvement of Left Ventricular Systolic Function in Patients With Heart Failure With Reduced Ejection Fraction Caused by Non-ischemic Etiology

Launched by SAMSUNG MEDICAL CENTER · Feb 5, 2024

Keywords

ClinConnect Summary

This clinical trial is looking into a specific heart condition called coronary microvascular dysfunction (CMD) and how it relates to improving heart function in patients with heart failure who have a decreased ability to pump blood (known as reduced ejection fraction) due to non-heart-attack causes. The researchers want to understand how common CMD is in these patients and what it means for their heart health.

To join this study, participants need to be at least 19 years old and have signs of heart failure along with a reduced ejection fraction of 40% or lower, which means their heart isn't pumping effectively. They must also need a specific heart test called coronary angiography and be willing to sign a consent form to participate. Unfortunately, some individuals, such as those with severe blockages in their heart arteries or those needing major heart surgery, won't be eligible for this trial. If you participate, you can expect to undergo tests and evaluations to help researchers learn more about the relationship between CMD and heart function improvement, which could lead to better treatments for heart failure in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • a) Subject must be at least 19 years of age. b) Subject with symptoms or signs of HF (NYHA ≥2 dyspnea) and reduced ejection fraction (LVEF ≤ 40%) c) Subject who clinically need coronary angiography d) Subject who can voluntarily sign informed consent form
• Exclusion Criteria:
• • a) Subject with significant coronary artery stenosis on coronary angiography (diameter stenosis ≥90% or 50-90% with fractional flow reserve \[FFR\] ≤0.80) b) Subject scheduled for cardiac replacement therapy (heart transplantation or left ventricular assisted device \[LVAD\] implantation) c) HF due to restrictive cardiomyopathy, active myocarditis, or constrictive pericarditis d) Significant valvular heart disease requiring surgery e) Subject who have non-cardiac co-morbid conditions with life expectancy \<1 year